Cabozantinib S-malate
Phase 2CompletedDevelopment Stage
Poorly Differentiated Thyroid Gland Carcinoma
Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Follicular Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IVA Thyroid Gland Follicular Carcinoma, Stage IVA Thyroid Gland Papillary Carcinoma, Stage IVB Thyroid Gland Follicular Carcinoma, Stage IVB Thyroid Gland Papillary Carcinoma, Stage IVC Thyroid Gland Follicular Carcinoma, Stage IVC Thyroid Gland Papillary Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Oncocytic Follicular Carcinoma
May 8, 2013 → Oct 9, 2017
About Cabozantinib S-malate
Cabozantinib S-malate is a phase 2 stage product being developed by Exelixis for Poorly Differentiated Thyroid Gland Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01811212. Target conditions include Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma.
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04220229 | Phase 1/2 | Terminated |
| NCT01811212 | Phase 2 | Completed |
Competing Products
1 competing product in Poorly Differentiated Thyroid Gland Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |